Novartis: GCAptAIN Study Fails To Meet Primary Endpoint At Week 52
3/7 07:52
(RTTNews) - Novartis reported top-line results from the Phase III GCAptAIN study evaluating Cosentyx in adults with newly diagnosed or relapsing giant cell arteritis. The company said Cosentyx did not demonstrate a statistically significant improvement in sustained remission at W...